250 related articles for article (PubMed ID: 25944167)
1. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.
Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC
J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312
[TBL] [Abstract][Full Text] [Related]
5. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract][Full Text] [Related]
6. Fas/FasL promoter gene polymorphism in patients with rheumatoid arthritis.
Kobak Ş; Berdeli A
Reumatismo; 2012 Dec; 64(6):374-9. PubMed ID: 23285481
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
Sun T; Miao X; Zhang X; Tan W; Xiong P; Lin D
J Natl Cancer Inst; 2004 Jul; 96(13):1030-6. PubMed ID: 15240787
[TBL] [Abstract][Full Text] [Related]
8. [Relationship between FAS/FASL gene polymorphisms and susceptibility of coal worker's pneumoconiosis].
Ni CH; Song ZF; Jia XM; Li AP; Li CP; Li SK; Li YM; Wang ZL; Zhou Y; Wang SY; Zhang ZD; Zhou JW
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Sep; 25(9):532-6. PubMed ID: 17997887
[TBL] [Abstract][Full Text] [Related]
9. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer].
Yang S; Miao XP; Zhang XM; Sun T; Qu SN; Xiong P; Ye YJ; Guo YL; Tan W; Wang S; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2132-5. PubMed ID: 16313826
[TBL] [Abstract][Full Text] [Related]
10. Functional genetic variants in apoptosis-associated FAS and FASL genes and risk of bladder cancer in a Turkish population.
Verim L; Timirci-Kahraman O; Akbulut H; Akbas A; Ozturk T; Turan S; Yaylim I; Ergen A; Ozturk O; Isbir T
In Vivo; 2014; 28(3):397-402. PubMed ID: 24815844
[TBL] [Abstract][Full Text] [Related]
11. FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.
Zhao H; Chen W; Du P; Sun A; Zhuang C; Tong J; Wang L
Tumour Biol; 2015 Jun; 36(6):4319-26. PubMed ID: 25596086
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
13. [Polymorphisms of FAS and FASL genes and susceptibility of silicosis].
Wu F; Qu YB; Sun P; Ji F; Qiu YL; Miao WB; Wang W; Jin RF; Xia ZL
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):7-11. PubMed ID: 18302883
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection.
Zamani AG; Barlas IO; Durakbasi-Dursun G; Ural O; Erdal E; Yildirim MS
Int J Immunogenet; 2013 Dec; 40(6):482-7. PubMed ID: 23560484
[TBL] [Abstract][Full Text] [Related]
15. Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer.
Gu D; Du M; Tang C; Chu H; Xu Z; Huo X; Gong W; Tang Y; Zhou J; Tong N; Xu Y; Zhang Z; Wang M; Chen J
Environ Mol Mutagen; 2014 Jun; 55(5):421-7. PubMed ID: 24535941
[TBL] [Abstract][Full Text] [Related]
16. Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.
Nallapalle SR; Daripally S; Prasad VT
Tumour Biol; 2015 Apr; 36(4):2709-24. PubMed ID: 25472583
[TBL] [Abstract][Full Text] [Related]
17. Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma.
Zhang W; Li C; Wang J; He C
Hepatogastroenterology; 2012; 59(113):141-6. PubMed ID: 21940365
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: gene-gene interactions in high-risk Indians.
Karimi MY; Kapoor V; Sharma SC; Das SN
Cancer Invest; 2013 Jan; 31(1):1-6. PubMed ID: 23153021
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck.
Zhang Z; Wang LE; Sturgis EM; El-Naggar AK; Hong WK; Amos CI; Spitz MR; Wei Q
Clin Cancer Res; 2006 Sep; 12(18):5596-602. PubMed ID: 17000697
[TBL] [Abstract][Full Text] [Related]
20. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
